Thai Foreign Minister Laments Placement On U.S. ‘Priority Watch List”
This article was originally published in PharmAsia News
Thailand's foreign minister said he was disappointed the United States decided to keep the country on its "priority watch list" of nations considered to have intellectual property rights protection issues. The minister did not mention the concerns of the United States regarding Thailand's compulsory licensing law targeting some foreign-made pharmaceuticals. Instead, he focused on the cooperation Thailand has given the United States in the area of stiffening actions against intellectual property piracy. The Office of U.S. Trade Representative said it remained concerned about the outcome of Thailand's compulsory licensing policy related to some foreign-made drugs. A USTR report said the agency is waiting to see if the new government retains the CL policy of the previous regime. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.